PT - JOURNAL ARTICLE AU - Zacharias, Martin AU - Kashofer, Karl AU - Wurm, Philipp AU - Regitnig, Peter AU - Schütte, Moritz AU - Neger, Margit AU - Ehmann, Sandra AU - Marsh, Leigh M. AU - Kwapiszewska, Grazyna AU - Loibner, Martina AU - Birnhuber, Anna AU - Leitner, Eva AU - Thüringer, Andrea AU - Winter, Elke AU - Sauer, Stefan AU - Pollheimer, Marion J. AU - Vagena, Fotini R. AU - Lackner, Carolin AU - Jelusic, Barbara AU - Ogilvie, Lesley AU - Durdevic, Marija AU - Timmermann, Bernd AU - Lehrach, Hans AU - Zatloukal, Kurt AU - Gorkiewicz, Gregor TI - Host and microbiome features of secondary infections in lethal covid-19 AID - 10.1101/2022.02.18.22270995 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.18.22270995 4099 - http://medrxiv.org/content/early/2022/02/19/2022.02.18.22270995.short 4100 - http://medrxiv.org/content/early/2022/02/19/2022.02.18.22270995.full AB - Secondary infections contribute significantly to covid-19 mortality but host and microbial factors driving this sequel remain poorly understood. We performed an autopsy study of 20 covid-19 cases and 14 controls from the first pandemic wave. Autopsies combined with microbial cultivation and deep RNA sequencing (RNAseq) allowed us to define major organ pathologies and specify secondary infections. Lethal covid-19 segregated into two main death causes separating cases with either dominant diffuse alveolar damage (DAD) or secondary infections of lungs. Lung microbiome changes were profound in covid-19 showing a reduced biodiversity and increased presence of prototypical bacterial and fungal pathogens in cases with secondary infections. Deep RNAseq of lung tissues distinctly mirrored death causes and cellular deconvolution stratified DAD cases into subgroups with different cellular compositions. Myeloid cells, including macrophages, and complement C1q activation were found to be strong stratifying factors suggesting a pathophysiological link possibly leading to tolerance in DAD subgroups. Moreover, several signs of immune-impairment were evident in covid-19 lungs including strong induction of inhibitory immune-checkpoints. Thus, our study highlights profound alterations of the local immunity in covid-19, wherein immune-impairment leads to reduced antimicrobial defense favoring the development of secondary infections on top of SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from the Austrian Science fund (FWF, DK-MOLIN W1241). The design of the BSL-3 laboratory used for autopsy of covid-19 cases was supported by the Eu-funded program "European Research Infrastructure for Highly Pathogenic Agents" (ERINHA-Advance, Grant agreement 824061).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the Medical University of Graz (EK number: 32_362 ex 19/20)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and supplemental material; nucleic acid data is deposited in ENA under the acc. no. PRJEB45873. https://www.ebi.ac.uk/ena/browser/home